The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Facing an upcoming surgical procedure often brings stress and anxiety, but not for Della de Corse. When she learned she would ...

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Do all heart valve replacements need open-heart surgery? Let's know the new techniques that could change everything ...

Saint Alphonsus in Boise earned a three-star TAVR ranking from STS and ACC, placing it among the nation’s top heart programs ...

The advancements of minimally invasive cardiac surgery for seniors often give them a better chance for a speedy recovery, as ...

Cleveland Clinic has entered into an agreement with DASI Simulations to co-develop artificial intelligence-based predictive ...

In July, CMS proposed a significant expansion of the covered procedures list for ASCs, which included many cardiovascular procedures. Here’s what five leaders have said about the expansion of ...